AU2019275044B2 - Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof - Google Patents

Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof Download PDF

Info

Publication number
AU2019275044B2
AU2019275044B2 AU2019275044A AU2019275044A AU2019275044B2 AU 2019275044 B2 AU2019275044 B2 AU 2019275044B2 AU 2019275044 A AU2019275044 A AU 2019275044A AU 2019275044 A AU2019275044 A AU 2019275044A AU 2019275044 B2 AU2019275044 B2 AU 2019275044B2
Authority
AU
Australia
Prior art keywords
ctp
seq
peptide
hours
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019275044A
Other languages
English (en)
Other versions
AU2019275044A1 (en
Inventor
Maliha Zahid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2019275044A1 publication Critical patent/AU2019275044A1/en
Application granted granted Critical
Publication of AU2019275044B2 publication Critical patent/AU2019275044B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019275044A 2018-05-23 2019-05-22 Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof Active AU2019275044B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862675307P 2018-05-23 2018-05-23
US62/675,307 2018-05-23
US201862778033P 2018-12-11 2018-12-11
US62/778,033 2018-12-11
US201962811077P 2019-02-27 2019-02-27
US62/811,077 2019-02-27
PCT/US2019/033551 WO2019226785A1 (en) 2018-05-23 2019-05-22 Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof

Publications (2)

Publication Number Publication Date
AU2019275044A1 AU2019275044A1 (en) 2020-12-17
AU2019275044B2 true AU2019275044B2 (en) 2025-06-26

Family

ID=68617073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019275044A Active AU2019275044B2 (en) 2018-05-23 2019-05-22 Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof

Country Status (8)

Country Link
US (2) US20210206805A1 (https=)
EP (1) EP3811451A4 (https=)
JP (1) JP2021525246A (https=)
KR (1) KR20210022575A (https=)
CN (1) CN112512546A (https=)
AU (1) AU2019275044B2 (https=)
CA (1) CA3100943A1 (https=)
WO (1) WO2019226785A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210712A2 (en) 2019-04-10 2020-10-15 Coralluma Llc. Ir700 nanocompositions for cardiac therapies and applications
WO2021087037A1 (en) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
EP4531869A2 (en) * 2022-05-31 2025-04-09 Georgetown University Use of conjugates of microrna and cardiac targeting peptides for treating heart failure
AU2024314139A1 (en) 2023-06-20 2026-01-08 Kuva Labs Inc. Methods for magnetic resonance molecular imaging of nanoconstructs and uses thereof
ES2953301B2 (es) * 2023-09-25 2024-06-03 Univ Madrid Complutense Péptido para el tratamiento de enfermedades cardiacas
WO2025106145A1 (en) * 2023-11-13 2025-05-22 Mayo Foundation For Medical Education And Research Hybrid form of cardiac targeting peptide with increased serum stability and enhanced cardiomyocyte targeting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244136A1 (en) * 2010-10-14 2012-09-27 Paul David Robbins Cardiac-Specific Protein Targeting Domain
US20150328315A1 (en) * 2012-04-23 2015-11-19 The Regents Of The University Of Michigan Systems and methods for targeted imaging and ablation of cardiac cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063576A (en) * 1998-06-29 2000-05-16 University Of Utah Research Foundation Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
RS91004A (sr) * 2002-04-15 2007-02-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Postupci za lečenje ileusa
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
US8460658B2 (en) * 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2010033868A2 (en) * 2008-09-19 2010-03-25 Taligen Therapeutics, Inc. Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
AU2010305284A1 (en) * 2009-10-06 2012-05-03 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
EP2928502B1 (en) * 2012-12-05 2019-01-23 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
WO2014093251A1 (en) * 2012-12-10 2014-06-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Engineered receptors and their use
US9550981B2 (en) * 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
WO2018090042A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Methods of treating heart failure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244136A1 (en) * 2010-10-14 2012-09-27 Paul David Robbins Cardiac-Specific Protein Targeting Domain
US20150328315A1 (en) * 2012-04-23 2015-11-19 The Regents Of The University Of Michigan Systems and methods for targeted imaging and ablation of cardiac cells

Also Published As

Publication number Publication date
KR20210022575A (ko) 2021-03-03
JP2021525246A (ja) 2021-09-24
WO2019226785A1 (en) 2019-11-28
EP3811451A1 (en) 2021-04-28
AU2019275044A1 (en) 2020-12-17
EP3811451A4 (en) 2022-04-06
CA3100943A1 (en) 2019-11-28
US20230406882A1 (en) 2023-12-21
WO2019226785A8 (en) 2020-06-18
US20210206805A1 (en) 2021-07-08
CN112512546A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
AU2019275044B2 (en) Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof
RU2548807C2 (ru) Пептиды, проникающие в клетку
US10189876B2 (en) Cell penetrating peptides for intracellular delivery of molecules
US10407477B2 (en) Conjugated knottin mini-proteins containing non-natural amino acids
ES2822942T3 (es) Formulaciones de productos biológicos para instilación intravesical
AU2008296733A1 (en) VEGFR-1/NRP-1 targeting peptides
JP2022511307A (ja) αコネキシンＣ末端ペプチドを用いるナノ粒子製剤およびその方法
Shinga et al. L17ER4: A cell-permeable attenuated cationic amphiphilic lytic peptide
US20220315625A1 (en) Lung-specific targeting-peptide (ltp), compositions, and uses thereof
US20240197896A1 (en) Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery
US20230144488A1 (en) Cell-penetrating peptide and use thereof
US20240182521A1 (en) Cell-penetrating peptide variant and use thereof
WO2017190619A1 (zh) 一种能抑制金葡菌毒素的化学合成环七修饰肽及其应用
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
US20260049107A1 (en) Artificial viral capsid
WO2022139071A1 (ko) 신규한 세포 투과성 펩타이드 및 이의 용도
CN112020555A (zh) 肽及其应用
TW202509086A (zh) c－Met蛋白質結合肽複合物
CN120435304A (zh) Ccr2抑制剂及使用方法
CN111440227B (zh) 一种抑制肿瘤转移及骨肿瘤的多肽及其应用
WO2024251939A2 (en) Ccr1 modulators and methods of use
WO2024037263A1 (zh) 一种体内低毒性的抑制金葡菌毒素产生的合成肽及其应用
JP2007143454A (ja) 細胞膜通過性ペプチド
TW202434613A (zh) 人類運鐵蛋白受體結合肽
WO2025047927A1 (ja) Ｖｅｇｆｒ－２アゴニスト活性を有するペプチド複合体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)